<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Gossamer-Bio-Inc-US38341P1021">Gossamer Bio, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/gossamer-bio-inc-goss-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302782955.html">Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit</a>
    </div>

      <div class="me-0 me-md-5">
        LOS ANGELES, May 27, 2026 /PRNewswire/ -- Glancy Prongay Wolke &amp; Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Gossamer Bio, Inc. (&quot;Gossamer&quot; or the &quot;Company&quot;) (NASDAQ: GOSS). IF YOU SUFFERED A LOSS ON YOUR GOSSAMER INVESTMENTS, CLICK  HERE  BEFORE JUNE 1, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Gossamer-Bio-Inc-US38341P1021">Gossamer Bio, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/gossamer-bio-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--goss-302782574.html">Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GOSS</a>
    </div>

      <div class="me-0 me-md-5">
        LOS ANGELES, May 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. (&quot;Gossamer&quot; or &quot;the Company&quot;) (NASDAQ: GOSS) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of GOSS during the class perio...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Gossamer-Bio-Inc-US38341P1021">Gossamer Bio, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/26/3301532/0/en/Bragar-Eagel-Squire-P-C-Urges-Gossamer-Bio-Inc-NASDAQ-GOSS-Investors-with-Large-Losses-to-Contact-the-Firm-Before-Monday-June-1st.html">Bragar Eagel &amp; Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st</a>
    </div>

      <div class="me-0 me-md-5">
        Bragar Eagel &amp; Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Gossamer (GOSS) To Contact Him Directly To Discuss Their Options
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Gossamer-Bio-Inc-US38341P1021">Gossamer Bio, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/gossamer-bio-inc-goss-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302780337.html">Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit</a>
    </div>

      <div class="me-0 me-md-5">
        LOS ANGELES, May 22, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Gossamer Bio, Inc. (&quot;Gossamer&quot; or the &quot;Company&quot;) (NASDAQ: GOSS) have opportunity to lead the securities fraud class action lawsuit.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Gossamer-Bio-Inc-US38341P1021">Gossamer Bio, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/goss-investors-have-opportunity-to-lead-gossamer-bio-inc-securities-fraud-lawsuit-302775437.html">GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, May 18, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the &quot;Class Period&quot;), of the important June 1, 2026 lead plaintiff deadline. So What: If you purchased Gossamer securities during the Class Period you may be entitled to compens...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Gossamer-Bio-Inc-US38341P1021">Gossamer Bio, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/18/3296936/34548/en/Deadline-Alert-Gossamer-Bio-Inc-GOSS-Shareholders-Who-Lost-Money-Urged-To-Contact-Glancy-Prongay-Wolke-Rotter-LLP-About-Securities-Fraud-Lawsuit.html">Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke &amp; Rotter LLP About Securities Fraud Lawsuit</a>
    </div>

      <div class="me-0 me-md-5">
        LOS ANGELES, May 18, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke &amp; Rotter LLP reminds investors of the upcoming June 1, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Pe...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Gossamer-Bio-Inc-US38341P1021">Gossamer Bio, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260518442485/en/Gossamer-Bio-Inc.-Launches-Exchange-Offer-and-Consent-Solicitation-Intended-to-Eliminate-Over-120-Million-of-Debt-with-Existing-Noteholder-Support/">Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support</a>
    </div>

      <div class="me-0 me-md-5">
        SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has commenced an exchange offer (the “Exchange Offer”) to exchan...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Gossamer-Bio-Inc-US38341P1021">Gossamer Bio, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260518356585/en/Gossamer-Bio-Announces-First-Quarter-2026-Financial-Results-and-Provides-Business-Update/">Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update</a>
    </div>

      <div class="me-0 me-md-5">
        SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 202...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Gossamer-Bio-Inc-US38341P1021/load_more?page=4">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>